ZBH
Zimmer Biomet Holdings, Inc. NYSE Listed Jul 25, 2001$83.42
Mkt Cap $16.1B
52w Low $79.83
12.6% of range
52w High $108.29
50d MA $91.38
200d MA $94.73
P/E (TTM)
23.3x
EV/EBITDA
11.2x
P/B
1.3x
Debt/Equity
0.6x
ROE
5.5%
P/FCF
12.1x
RSI (14)
—
ATR (14)
—
Beta
0.61
50d MA
$91.38
200d MA
$94.73
Avg Volume
2.3M
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
345 East Main Street · Warsaw, IN 46580 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 1.86 | 2.09 | +12.4% | 82.80 | -0.9% | -3.3% | -0.4% | +0.1% | -0.2% | +0.3% | — |
| Feb 10, 2026 | TNS | 2.38 | 2.42 | +1.7% | 91.40 | -0.6% | +4.6% | +4.1% | +5.5% | +6.3% | +7.5% | — |
| Nov 5, 2025 | TNS | 1.87 | 1.90 | +1.6% | 87.55 | -1.7% | +1.1% | +1.1% | +1.3% | +1.1% | +2.8% | — |
| Aug 7, 2025 | TNS | 1.98 | 2.07 | +4.5% | 98.43 | +0.6% | +0.8% | +1.6% | +3.4% | +4.9% | +3.7% | — |
| May 5, 2025 | TNS | 1.77 | 1.81 | +2.3% | 90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% | — |
| Feb 6, 2025 | TNS | 2.30 | 2.31 | +0.4% | 102.69 | +0.2% | -1.7% | -2.2% | -3.6% | -3.6% | -2.7% | — |
| Oct 30, 2024 | TNS | 1.74 | 1.74 | +0.0% | 109.81 | -0.1% | -2.6% | -2.3% | -1.3% | -0.8% | +0.3% | — |
| Aug 7, 2024 | TNS | 1.99 | 2.01 | +1.0% | 105.81 | +0.2% | +2.7% | +2.1% | +1.1% | +3.3% | +2.7% | — |
| May 2, 2024 | TNS | 1.87 | 1.94 | +3.7% | 118.46 | +0.9% | +2.7% | +1.8% | +2.5% | +2.0% | +2.5% | — |
| Feb 8, 2024 | TNS | 2.15 | 2.20 | +2.3% | 123.04 | +0.7% | -0.2% | +2.3% | +0.1% | -1.0% | +1.1% | — |
| Nov 7, 2023 | TNS | 1.59 | 1.65 | +3.8% | 105.93 | +0.0% | -1.0% | -1.7% | -0.5% | -0.1% | +2.0% | — |
| Aug 1, 2023 | TNS | 1.82 | 1.82 | +0.0% | 132.27 | -0.4% | -2.9% | -4.9% | -4.5% | -5.0% | -5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Citigroup | Maintains | Neutral → Neutral | — | $82.80 | $82.03 | -0.9% | -3.3% | -0.4% | +0.1% | -0.2% | +0.3% |
| Apr 29 | JP Morgan | Maintains | Neutral → Neutral | — | $82.80 | $82.03 | -0.9% | -3.3% | -0.4% | +0.1% | -0.2% | +0.3% |
| Apr 29 | Truist | Maintains | Hold → Hold | — | $82.80 | $82.03 | -0.9% | -3.3% | -0.4% | +0.1% | -0.2% | +0.3% |
| Apr 29 | Citizens | Maintains | Market Outperform → Market Outperform | — | $82.80 | $82.03 | -0.9% | -3.3% | -0.4% | +0.1% | -0.2% | +0.3% |
| Apr 29 | Stifel | Maintains | Buy → Buy | — | $82.80 | $82.03 | -0.9% | -3.3% | -0.4% | +0.1% | -0.2% | +0.3% |
| Apr 29 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $82.80 | $82.03 | -0.9% | -3.3% | -0.4% | +0.1% | -0.2% | +0.3% |
| Apr 29 | Barclays | Maintains | Underweight → Underweight | — | $82.80 | $82.03 | -0.9% | -3.3% | -0.4% | +0.1% | -0.2% | +0.3% |
| Mar 23 | BTIG | Downgrade | Buy → Neutral | — | $87.87 | $88.73 | +1.0% | -0.1% | -1.8% | -0.3% | +1.5% | +0.8% |
| Feb 12 | Barclays | Maintains | Underweight → Underweight | — | $95.61 | $95.55 | -0.1% | -0.4% | +0.9% | +1.6% | +2.8% | +3.8% |
| Feb 11 | Citigroup | Maintains | Neutral → Neutral | — | $91.40 | $90.87 | -0.6% | +4.6% | +4.1% | +5.5% | +6.3% | +7.5% |
| Feb 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $91.40 | $90.87 | -0.6% | +4.6% | +4.1% | +5.5% | +6.3% | +7.5% |
| Feb 10 | BTIG | Maintains | Buy → Buy | — | $89.73 | $94.15 | +4.9% | +1.9% | +6.6% | +6.1% | +7.5% | +8.3% |
| Feb 10 | Needham | Maintains | Hold → Hold | — | $89.73 | $94.15 | +4.9% | +1.9% | +6.6% | +6.1% | +7.5% | +8.3% |
| Jan 28 | UBS | Maintains | Sell → Sell | — | $85.99 | $85.40 | -0.7% | -0.3% | +0.0% | +1.3% | +0.3% | +0.2% |
| Jan 9 | Bernstein | Maintains | Market Perform → Market Perform | — | $94.08 | $92.99 | -1.2% | -1.3% | -2.8% | -6.1% | -5.1% | -5.7% |
| Jan 8 | BTIG | Maintains | Buy → Buy | — | $92.67 | $91.94 | -0.8% | +1.5% | +0.2% | -1.3% | -4.7% | -3.7% |
| Jan 5 | Evercore ISI | Upgrade | In Line → Outperform | — | $90.02 | $90.27 | +0.3% | +2.9% | +5.3% | +2.9% | +4.5% | +3.1% |
| Dec 16 | Baird | Downgrade | Outperform → Neutral | — | $92.43 | $92.01 | -0.5% | -1.6% | -0.9% | -2.2% | -3.6% | -2.8% |
| Dec 11 | Citigroup | Maintains | Neutral → Neutral | — | $93.09 | $93.00 | -0.1% | -0.7% | -1.6% | -0.7% | -2.3% | -1.6% |
| Nov 10 | Canaccord Genuity | Maintains | Hold → Hold | — | $88.50 | $87.96 | -0.6% | +0.3% | +0.0% | +1.7% | +2.3% | +1.6% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $87.55 | $86.07 | -1.7% | +1.1% | +1.1% | +1.3% | +1.1% | +2.8% |
| Nov 6 | Barclays | Maintains | Underweight → Underweight | — | $87.55 | $86.07 | -1.7% | +1.1% | +1.1% | +1.3% | +1.1% | +2.8% |
| Nov 6 | UBS | Maintains | Sell → Sell | — | $87.55 | $86.07 | -1.7% | +1.1% | +1.1% | +1.3% | +1.1% | +2.8% |
| Nov 6 | JP Morgan | Downgrade | Overweight → Neutral | — | $87.55 | $86.07 | -1.7% | +1.1% | +1.1% | +1.3% | +1.1% | +2.8% |
| Nov 5 | Barclays | Maintains | Underweight → Underweight | — | $103.18 | $90.66 | -12.1% | -15.1% | -14.2% | -14.2% | -14.0% | -14.2% |
| Nov 5 | BTIG | Maintains | Buy → Buy | — | $103.18 | $90.66 | -12.1% | -15.1% | -14.2% | -14.2% | -14.0% | -14.2% |
| Oct 22 | Canaccord Genuity | Maintains | Hold → Hold | — | $102.69 | $103.49 | +0.8% | +1.3% | +0.5% | +0.3% | +0.4% | -1.5% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $94.71 | $94.91 | +0.2% | +0.4% | +3.9% | +4.9% | +5.5% | +7.6% |
| Oct 7 | Evercore ISI | Maintains | In Line → In Line | — | $98.83 | $99.43 | +0.6% | +0.2% | -0.5% | -1.5% | -4.2% | -3.8% |
| Sep 19 | Stifel | Maintains | Buy → Buy | — | $100.21 | $101.15 | +0.9% | -0.1% | +1.5% | +0.1% | -1.2% | -3.2% |
| Aug 8 | UBS | Maintains | Sell → Sell | — | $98.43 | $98.98 | +0.6% | +0.8% | +1.6% | +3.4% | +4.9% | +3.7% |
| Aug 8 | Raymond James | Maintains | Outperform → Outperform | — | $98.43 | $98.98 | +0.6% | +0.8% | +1.6% | +3.4% | +4.9% | +3.7% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $98.43 | $98.98 | +0.6% | +0.8% | +1.6% | +3.4% | +4.9% | +3.7% |
| Jul 8 | Evercore ISI | Maintains | In Line → In Line | — | $92.57 | $92.34 | -0.2% | +1.0% | +2.8% | +2.8% | +1.3% | +1.4% |
| May 12 | Canaccord Genuity | Maintains | Hold → Hold | — | $95.21 | $96.64 | +1.5% | +3.2% | +2.4% | +0.1% | +1.6% | +1.8% |
| May 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $92.27 | $92.85 | +0.6% | +2.0% | +3.1% | +3.2% | +6.4% | +5.7% |
| May 6 | Baird | Maintains | Outperform → Outperform | — | $90.48 | $90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% |
| May 6 | Goldman Sachs | Maintains | Neutral → Neutral | — | $90.48 | $90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $90.48 | $90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% |
| May 6 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $90.48 | $90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% |
| May 6 | Raymond James | Maintains | Outperform → Outperform | — | $90.48 | $90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% |
| May 6 | JP Morgan | Maintains | Overweight → Overweight | — | $90.48 | $90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% |
| May 6 | RBC Capital | Maintains | Outperform → Outperform | — | $90.48 | $90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% |
| May 6 | Stifel | Maintains | Buy → Buy | — | $90.48 | $90.48 | +0.0% | +2.0% | +4.0% | +5.1% | +5.2% | +8.6% |
| Feb 10 | Barclays | Maintains | Underweight → Underweight | — | $100.93 | $101.57 | +0.6% | -0.5% | -1.9% | -1.9% | -1.0% | -0.4% |
| Feb 10 | Truist | Maintains | Hold → Hold | — | $100.93 | $101.57 | +0.6% | -0.5% | -1.9% | -1.9% | -1.0% | -0.4% |
| Feb 7 | Raymond James | Maintains | Outperform → Outperform | — | $102.69 | $102.94 | +0.2% | -1.7% | -2.2% | -3.6% | -3.6% | -2.7% |
| Feb 7 | RBC Capital | Maintains | Outperform → Outperform | — | $102.69 | $102.94 | +0.2% | -1.7% | -2.2% | -3.6% | -3.6% | -2.7% |
| Feb 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $102.69 | $102.94 | +0.2% | -1.7% | -2.2% | -3.6% | -3.6% | -2.7% |
| Feb 7 | Needham | Maintains | Hold → Hold | — | $102.69 | $102.94 | +0.2% | -1.7% | -2.2% | -3.6% | -3.6% | -2.7% |
No insider trades available.
8-K · 5.02
!!! Very High
Zimmer Biomet Holdings, Inc. -- 8-K 5.02: Executive Change
Zimmer Biomet appointed Suketu Upadhyay as interim CFO and Paul Stellato as principal financial officer while Upadhyay resigned as director, signaling leadership transitions in the orthopedic device company's finance function.
Apr 28
8-K
Zimmer Biomet Holdings, Inc. -- 8-K Filing
Zimmer Biomet reported Q1 2026 financial results with Phipps appointed as Senior Vice President of Chief Legal and Corporate Affairs Officer and Secretary.
Apr 28
8-K · 5.02
!!! Very High
SkinHealth Systems Inc. -- 8-K 5.02: Executive Change
SkinHealth Systems appointed Kenneth Tripp as director and Dr. Sachin Shridharani as Senior Vice President, signaling management strengthening under new leadership.
Apr 22
8-K
Zimmer Biomet Holdings, Inc. -- 8-K Filing
Zimmer Biomet reported full-year 2025 financial results, providing investors with updated performance metrics and operational guidance for the orthopedic device manufacturer.
Feb 10
Data updated apr 27, 2026 11:32am
· Source: massive.com